Imaging and Radiation Sciences

UWCCC成像和辐射科学项目摘要 联合领导人：罗伯特·杰拉伊和兰迪·金普尔 项目摘要/摘要 成像和辐射科学(IR)计划的使命是将物理和生物科学与 临床研究和临床实践，以提高癌症诊断、治疗和癌症患者的生活水平。 UWCCC和IR计划内的特殊环境提供了一个推进的机会 影像、放射性药物、分子靶向放射生物学和放射治疗 科学的范围从基本机制到临床试验。这些目标是通过三个方面实现的 相互关联的目标。目标1：开发和转化创新的成像试剂和技术，以改善 癌症检测和治疗反应评估。IR计划成员专注于开发和 新型分子显像剂的翻译，如放射性标记纳米材料，定量 成像方法，以及创新图像分析技术的发展，包括先进的人工 智能方法。目标2：开发和转化放射性药物以实现更有效 全身放射治疗的个性化。IR计划成员专注于小说的开发 正电子和低能电子发射放射性核素和放射性药物运载工具的组合 放射性药物的免疫治疗，以及治疗药物的开发和临床翻译。 目标3：发展和转化局部放射治疗管理方面的进展，以改进 治疗反应，最大限度地减少副作用。IR计划成员专注于局部肿瘤消融， 将局部治疗与全身治疗相结合以靶向寡耐药，了解分子 治疗耐药的潜在机制，并通过新的细胞疗法减少治疗毒性 并通过使用独特的成像和治疗计划的组合来提高治疗质量 干预措施。自上次CCSG更新以来取得的显著成就包括临床试验收益翻了一番 与上次CCSG续签的时间相比，全国范围内翻译的许多试验反映了 近40%的IR成员在合作小组中担任领导职务。IR成员已收到多个 大型多调查者研究包括免疫/放射性药物P01，UG3/UH3支持第一个- 细胞疗法治疗放射性口干症的人体研究一直处于关键领先地位 在头颈癌孢子更新以及乳腺癌和前列腺癌孢子更新中的作用(受到好评) 资助金申请。这些富有成效的努力得到了很好的支持：来自6个部门的41名成员总共有 年度直接成本为980万美元(来自NCI的340万美元，比上一个周期翻了一番)。这些研究工作已经取得了 在过去五年资助期内发表了897篇同行评议的出版物，其中期刊占19% 影响因素&>10，方案内出版物从2017年的14%增加到2022年的31% 方案间同期从12%增加到18%。

UWCCC Imaging and Radiation Sciences Program Summary Co-Leaders: Robert Jeraj and Randy Kimple PROJECT SUMMARY/ABSTRACT The Imaging and Radiation Sciences (IR) Program’s mission is to integrate physical and biological sciences with clinical research and clinical practice to improve cancer diagnosis, therapy, and the lives of patients with cancer. The exceptional environment within the UWCCC and the IR program provides an opportunity to advance imaging, radiopharmaceutical, molecularly-targeted radiobiology, and radiation therapy across the translational science spectrum from basic mechanisms through clinical trials. These goals are achieved through three connected aims. Aim 1: To develop and translate innovative imaging agents and technologies to improve cancer detection and treatment response assessments. IR program members focus on development and translation of novel molecular imaging agents, such as radiolabeled nanomaterials, refinement of quantitative imaging methods, and development of innovative image-analysis techniques, including advanced artificial intelligence methods. Aim 2: To develop and translate radiopharmaceuticals for more effective personalization of systemic radiation therapies. IR program members focus on development of novel positron and low energy electron-emitting radionuclides and radiopharmaceutical delivery vehicles, combinations of radiopharmaceuticals with immunotherapy, and the development and clinical translation of theranostic agents. Aim 3: To develop and translate advances in the management of localized radiation therapies to improve therapeutic response and minimize side effects. IR program members focus on localized tumor ablation, combining localized therapies with systemic therapies to target oligo-resistance, understanding molecular mechanisms underlying therapeutic resistance, and reducing treatment toxicities through novel cellular therapies and by employing unique combinations of imaging and treatment planning to improve the quality of therapeutic interventions. Notable achievements since the last CCSG renewal include doubling clinical trial accrual compared to the time of the last CCSG renewal, with many of trials being translated nationwide reflected by almost 40% of IR members holding leadership roles in cooperative groups. IR members have received multiple large multi-investigator studies including an Immuno/Radiopharmaceutical P01, a UG3/UH3 supporting a first- in-human study of cell therapy for treatment of radiation-induced xerostomia and have been in key leadership roles in the Head and Neck cancer SPORE renewal (favorably reviewed) and breast and prostate cancer SPORE grant submissions. These productive efforts are well supported: 41 members from 6 departments have a total of $9.8M in annual direct costs ($3.4M from NCI, double compared to the prior cycle). These research efforts have led to 897 peer-reviewed publications in the last five-year funding period, including an exceptional 19% in journals with impact factors >10, with intra-programmatic publications increasing from 14% in 2017 to 31% in 2022 and inter-programmatic increasing from 12% to 18% over the same time.